peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Notice of extraordinary meeting of shareholders in Hansa Medical AB (publ)

14 Feb 2014, 14:11
Regulatory information
Shareholders in Hansa Medical AB (publ) are hereby given notice of the extraordinary meeting of shareholders on 5 March 2014, 13.00), to be held in the lecture theatre at the company’s premises on Scheelevägen 22 in Lund. Doors open at 12.30.

Right to participation
The right to participate in the extraordinary meeting of shareholders is extended to those who are both entered in the share register, administered by Euroclear Sweden AB, as per 27 February 2014, and who have registered their intention to participate in the extraordinary meeting no later than 12.00 on 27 February 2014.

In order that shareholders who have their shares registered with an authorized nominee shall have the right to participate in the extraordinary meeting such shareholders must temporarily re-register their shares in their own names. Such re-registration must be accomplished with Euroclear Sweden AB no later than 27 February 2014. This implies that the shareholders must inform the nominees of such re-registration in good time prior to this date.

Registration of participation
Registration of participation in the extraordinary meeting can be submitted in writing to the address Hansa Medical AB, Box 785, 220 07 Lund, via e-mail to the address, per telephone at the number +46(0)46-165670 or per fax at the number +46(0)46-127775. The shareholder’s name, address, personal identity number/corporate identity number, number of shares held and daytime telephone number must be provided upon registration. If applicable, the number of assistants (maximum of two) must also be provided. Shareholders who are intending to be represented by a proxy must attach a dated, written power of attorney and other authorization documents to their registration. The originals of these authorization documents must be produced upon request at the extraordinary meeting. A power of attorney form is provided by Hansa Medical and will be sent to shareholders upon request. In addition, the form will be accessible through the corporate web site at the latest three weeks prior to the extraordinary meeting.

Proposed agenda

  1. Opening of the meeting
  2. Election of chairman of the meeting
  3. Preparation and approval of voting list
  4. Approval of proposed agenda
  5. Election of one or two persons to verify the minute
  6. Confirmation that the meeting has been properly convened
  7. Resolution regarding share issue with preferential rights
  8. Authorization for CEO to make minor adjustments in resolution under item 7 in order for execution and registration of the resolution
  9. Close of extraordinary meeting

For further information, see attached full notice in Swedish or contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.